Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 221

Sort by

Sort Order Select

Journal Articles

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, Matthew S. Davids, Jeff P. Sharman, Nilanjan Ghosh, Yang Feng, Mary Jean Fusco, Jacqueline Hilger-Rolfe, Chen Qian, Wendy J. Sinai, Sophie Wimberley, John F. Seymour

Blood (2024) 144 (Supplement 1): 6784.

https://doi.org/10.1182/blood-2024-207716

Published: 2024

Journal Articles

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

Blood (2024) 144 (Supplement 1): 582.

https://doi.org/10.1182/blood-2024-204930

Published: 2024

Journal Articles

Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era

Victor S. Lin, Sean Harrop, Sean J. McKeague, Rory Bennett, Adrian Minson, Divya V. Somasekharannair, Edward Chew, Cameron Snell, Stephen Lade, Philip A. Thompson, John F. Seymour, Michael J. Dickinson, Mary Ann Anderson

Blood (2024) 144 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2024-207849

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

John F. Seymour, Constantine S. Tam, Chan Y. Cheah, Ricardo D. Parrondo, John N. Allan, Judith Trotman, Ranjana H. Advani, Herbert A. Eradat, Pier Luigi Zinzani, Masa Lasica, Steven P. Treon, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Anna Maria Frustaci

Blood (2024) 144 (Supplement 1): 860.

https://doi.org/10.1182/blood-2024-199212

Published: 2024

Journal Articles

Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience

Hamish W Scott, Mark R Dowling, Daniel Garcia, Samantha van der Linde, Nicole O'Leary, Brydon Panozzo, Adrian Minson, James A Kuzich, Aaron Jun Ning Wong, Michael S Hofman, Monique Youl, Belinda Campbell, Michael Patrick Macmanus, Philip A. Thompson, Mary Ann Anderson, John F. Seymour, Michael J Dickinson, Simon J Harrison

Blood (2024) 144 (Supplement 1): 4511.

https://doi.org/10.1182/blood-2024-209767

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan C. Thompson, Ricardo D. Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfo, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, John F. Seymour

Blood (2024) 144 (Supplement 1): 885.

https://doi.org/10.1182/blood-2024-199116

Published: 2024

Journal Articles

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Blood (2024) 144 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2024-200701

Published: 2024

Journal Articles

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Blood (2024) 144 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2024-208727

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Constantine S. Tam, Anna Maria Frustaci, Fontanet Bijou, Pier Luigi Zinzani, John F. Seymour, Masa Lasica, Herbert A. Eradat, Victor T.G. Lin, Maan Alwan, Irina Mocanu, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Chan Y. Cheah

Blood (2024) 144 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2024-199154

Published: 2024

Journal Articles

Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Chan Y. Cheah, Amanda Jane Johnston, Joel Wight, Piers Blombery, Katharine L. Lewis, Rory Bennett, Jing Xie, Stella Vlahos, Joyce Gonzales, Sally Binks, John F. Seymour

Blood (2024) 144 (Supplement 1): 4410.

https://doi.org/10.1182/blood-2024-199108

Published: 2024

Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla

Blood (2024) 144 (10): 1061–1068.

https://doi.org/10.1182/blood.2023023659

Published: 2024

Includes: Supplemental data

Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood (2024) 144 (8): 867–872.

https://doi.org/10.1182/blood.2023023388

Published: 2024

Includes: Supplemental data

Journal Articles

Degraders upgraded: the rise of PROTACs in hematological malignancies

Joshua M. L. Casan, John F. Seymour

Blood (2024) 143 (13): 1218–1230.

https://doi.org/10.1182/blood.2023022993

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Blood (2024) 143 (8): 673–684.

https://doi.org/10.1182/blood.2023021306

Published: 2024

Includes: Supplemental data

Journal Articles

Risk/benefit of BTK/venetoclax combos: the context matters!

John F. Seymour

Blood (2024) 143 (7): 563–564.

https://doi.org/10.1182/blood.2023022896

Published: 2024

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 981.

https://doi.org/10.1182/blood-2023-181627

Published: 2023

Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2023-181108

Published: 2023

Journal Articles

Obinutuzumab, Lenalidomide and Venetoclax in Patients with Treatment-Naïve Advanced-Stage Follicular Lymphoma: First Results of the Investigator-Initiated Phase Ib/II, Multicenter Leverage Study

Chan Y. Cheah, Katharine L. Lewis, Rory Bennett, Amanda Jane Johnston, Joel Wight, Jing Xie, Stella Vlahos, Katrina Celeste, Sally Binks, John F. Seymour

Blood (2023) 142 (Supplement 1): 1659.

https://doi.org/10.1182/blood-2023-184660

Published: 2023

Journal Articles

Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib from 5 Prospective Clinical Trials

Jeff P. Sharman, Paolo Ghia, Paulo Andre P. Palhares De Miranda, Naghmana Bajwa, Simon Rule, Bob Shaw, John F. Seymour

Blood (2023) 142 (Supplement 1): 4643.

https://doi.org/10.1182/blood-2023-174913

Published: 2023

NARROW

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Degraders upgraded: the rise of PROTACs in hematological malignancies

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Risk/benefit of BTK/venetoclax combos: the context matters!

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Obinutuzumab, Lenalidomide and Venetoclax in Patients with Treatment-Naïve Advanced-Stage Follicular Lymphoma: First Results of the Investigator-Initiated Phase Ib/II, Multicenter Leverage Study

Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib from 5 Prospective Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only